Zhihua Sui
Zhihua Sui has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
James Lanter
Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, PA 19477, United States
3 shared publications- George Allan
Johnson & Johnson Pharmaceutical Research & Development L.L.C., Drug Discovery, 1000 Route 202, Raritan, NJ 08869, USA
2 shared publications Joseph Gunnet
Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, PA 19477, United States
2 shared publicationsOlivia Linton
Johnson & Johnson Pharmaceutical Research & Development L.L.C., Drug Discovery, 1000 Route 202, Raritan, NJ 08869, USA
2 shared publicationsScott G. Lundeen
Johnson & Johnson Pharmaceutical Research & Development L.L.C., Drug Discovery, 1000 Route 202, Raritan, NJ 08869, USA
2 shared publications- Xuqing Zhang
Discovery Sciences, Discovery Chemistry, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
2 shared publications
Latest Publications
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (15) , 3272-3278
Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (15) , 3272-3278
Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists
- 15 February 2013
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (4) , 1063-1069
A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists
- 15 February 2013
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (4) , 1063-1069
A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists
- 1 January 2011
- Published by Elsevier
- Vol. 493, 421-445
Medicinal Chemistry Inspired Fragment-Based Drug Discovery
- 1 January 2011
- Published by Elsevier
- Vol. 493, 421-445
Medicinal Chemistry Inspired Fragment-Based Drug Discovery
- 1 November 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (21) , 5754-5757
Synthesis and identification of novel 11β-aryl-4′,5′-dihydrospiro[estra-4,9-diene-17β,4′-oxazole] analogs with dissociated antiprogesterone activities
- 1 November 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (21) , 5754-5757
Synthesis and identification of novel 11β-aryl-4′,5′-dihydrospiro[estra-4,9-diene-17β,4′-oxazole] analogs with dissociated antiprogesterone activities
- 1 March 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (5) , 1471-1474
Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist
- 1 March 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (5) , 1471-1474
Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist
- 15 February 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (4) , 955-958
2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists
- 15 February 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (4) , 955-958
2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists
- 1 January 2003
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 13 (9) , 1373-1388
Phosphodiesterase-5 inhibitors for male erectile dysfunction
The success of sildenafil (Viagra®; Pfizer) as an oral therapy for male erectile dysfunction (MED) has greatly stimulated interest in phosphodiesterase (PDE)-5 inhibitors. A large number of compounds from a wide variety of structural classes have been identified as PDE5 inhibitors during the past few years. Many of them possess desirable biological and pharmaceutical profiles. Selected compounds from different structural classes have entered clinical trials for MED. Since PDE5 inhibition is now a proven mechanism for MED treatment, many of these compounds are scientifically capable of becoming drugs for MED, as evidenced by the recent launches of vardenafil (Levitra®; Bayer Yakuhin) and tadalafil (Cialis®; Lilly ICOS). However, the business environment rather than scientific merit will probably determine the journey of additional PDE5 inhibitors to the market.
- 1 January 2003
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 13 (9) , 1373-1388
Phosphodiesterase-5 inhibitors for male erectile dysfunction
The success of sildenafil (Viagra®; Pfizer) as an oral therapy for male erectile dysfunction (MED) has greatly stimulated interest in phosphodiesterase (PDE)-5 inhibitors. A large number of compounds from a wide variety of structural classes have been identified as PDE5 inhibitors during the past few years. Many of them possess desirable biological and pharmaceutical profiles. Selected compounds from different structural classes have entered clinical trials for MED. Since PDE5 inhibition is now a proven mechanism for MED treatment, many of these compounds are scientifically capable of becoming drugs for MED, as evidenced by the recent launches of vardenafil (Levitra®; Bayer Yakuhin) and tadalafil (Cialis®; Lilly ICOS). However, the business environment rather than scientific merit will probably determine the journey of additional PDE5 inhibitors to the market.